Logo image of INDP

INDAPTUS THERAPEUTICS INC (INDP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INDP - US45339J2042 - Common Stock

2.72 USD
0 (0%)
Last: 12/30/2025, 8:00:02 PM
2.6505 USD
-0.07 (-2.56%)
After Hours: 12/30/2025, 8:00:02 PM
Fundamental Rating

2

INDP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. INDP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INDP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INDP had negative earnings in the past year.
In the past year INDP has reported a negative cash flow from operations.
INDP had negative earnings in each of the past 5 years.
INDP had a negative operating cash flow in each of the past 5 years.
INDP Yearly Net Income VS EBIT VS OCF VS FCFINDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

INDP has a worse Return On Assets (-246.60%) than 92.08% of its industry peers.
Looking at the Return On Equity, with a value of -366.23%, INDP is doing worse than 74.53% of the companies in the same industry.
Industry RankSector Rank
ROA -246.6%
ROE -366.23%
ROIC N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
INDP Yearly ROA, ROE, ROICINDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

INDP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INDP Yearly Profit, Operating, Gross MarginsINDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, INDP has more shares outstanding
The number of shares outstanding for INDP has been increased compared to 5 years ago.
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDP Yearly Shares OutstandingINDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
INDP Yearly Total Debt VS Total AssetsINDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -20.61, we must say that INDP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.61, INDP is doing worse than 83.96% of the companies in the same industry.
INDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.61
ROIC/WACCN/A
WACCN/A
INDP Yearly LT Debt VS Equity VS FCFINDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

INDP has a Current Ratio of 2.88. This indicates that INDP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.88, INDP is doing worse than 65.66% of the companies in the same industry.
INDP has a Quick Ratio of 2.88. This indicates that INDP is financially healthy and has no problem in meeting its short term obligations.
INDP has a Quick ratio of 2.88. This is in the lower half of the industry: INDP underperforms 63.77% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
INDP Yearly Current Assets VS Current LiabilitesINDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.24% over the past year.
EPS 1Y (TTM)34.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.21% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.79%
EPS Next 2Y36.21%
EPS Next 3Y23.84%
EPS Next 5Y17.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INDP Yearly Revenue VS EstimatesINDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2028 2029 2030 2031 2032 100M 200M 300M 400M
INDP Yearly EPS VS EstimatesINDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INDP. In the last year negative earnings were reported.
Also next year INDP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INDP Price Earnings VS Forward Price EarningsINDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INDP Per share dataINDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as INDP's earnings are expected to grow with 23.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.21%
EPS Next 3Y23.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INDAPTUS THERAPEUTICS INC

NASDAQ:INDP (12/30/2025, 8:00:02 PM)

After market: 2.6505 -0.07 (-2.56%)

2.72

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-10 2026-03-10/amc
Inst Owners4.11%
Inst Owner Change-6.28%
Ins Owners10.22%
Ins Owner Change4.72%
Market Cap4.76M
Revenue(TTM)N/A
Net Income(TTM)-16.87M
Analysts82.86
Price Target10.2 (275%)
Short Float %1.16%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.75%
Min EPS beat(2)3.55%
Max EPS beat(2)29.94%
EPS beat(4)3
Avg EPS beat(4)-6.37%
Min EPS beat(4)-74.29%
Max EPS beat(4)29.94%
EPS beat(8)7
Avg EPS beat(8)7.24%
EPS beat(12)11
Avg EPS beat(12)11.71%
EPS beat(16)15
Avg EPS beat(16)18.53%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.93%
EPS NY rev (1m)4.29%
EPS NY rev (3m)4.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-31.67
EYN/A
EPS(NY)-6.56
Fwd EYN/A
FCF(TTM)-8.59
FCFYN/A
OCF(TTM)-8.59
OCFYN/A
SpS0
BVpS2.63
TBVpS2.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -246.6%
ROE -366.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -20.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.74%
EPS Next Y42.79%
EPS Next 2Y36.21%
EPS Next 3Y23.84%
EPS Next 5Y17.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.51%
OCF growth 3YN/A
OCF growth 5YN/A

INDAPTUS THERAPEUTICS INC / INDP FAQ

Can you provide the ChartMill fundamental rating for INDAPTUS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to INDP.


What is the valuation status of INDAPTUS THERAPEUTICS INC (INDP) stock?

ChartMill assigns a valuation rating of 1 / 10 to INDAPTUS THERAPEUTICS INC (INDP). This can be considered as Overvalued.


Can you provide the profitability details for INDAPTUS THERAPEUTICS INC?

INDAPTUS THERAPEUTICS INC (INDP) has a profitability rating of 0 / 10.